# Study of Erlotinib in Combination With Bortezomib

> **NCT00895687** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00895687
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895687, "Study of Erlotinib in Combination With Bortezomib". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00895687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*